CK Venture Capital invests in Medikura

By the end of 2019, it was a done deal. CK Venture Capital is investing in the company Medikura. By investing in the start-up, which was founded in 2017, Conny Hörl and Katja Ruhnke are getting involved in an industry they are no strangers to, healthcare. "Medikura's idea can revolutionize our healthcare system." Katja Ruhnke is convinced of that. 

Medikura operates the platform www.nebenwirkungen.de, where affected patients can quickly and easily report side effects of medicines and are forwarded directly to the pharmaceutical company concerned. Everything is strictly anonymized and encrypted in accordance with the applicable data protection regulations. By means of a complex system, the pharmaceutical company can consult with the patient and subsequently update package inserts or fulfill the legal reporting obligations quickly and cost-effectively. The goal is to establish a comprehensive infrastructure to optimally network authorities, pharmaceutical companies and patients. 

Medikura was founded by Dr. Friderike Bruchmann and Philipp Nägelein. The fact that a woman is at the helm of the young start-up naturally makes the female investors particularly happy.